Invivyd, Inc. is a biotechnology company focused on developing innovative therapies to address significant unmet medical needs in the field of infectious diseases. The company primarily concentrates on creating monoclonal antibody treatments designed to prevent and treat viral infections, thereby aiming to improve patient outcomes and enhance public health. With a commitment to leveraging cutting-edge research and development, Invivyd seeks to bring new and effective solutions to the market, ultimately striving to protect populations from the impact of various viral threats. Read More
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock at a price of $2.4999 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. All of the shares and pre-funded warrants are being offered by Invivyd. In addition, Invivyd has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,500,000 shares of Invivyd common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 19, 2025, subject to the satisfaction of customary closing conditions.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Invivyd. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Stay updated with the latest market activity on Friday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Invivyd (IVVD) reported mixed Q3 results, with revenue slightly missing estimates but EPS beating forecasts. The stock surged 9% as investors focused on cost control and progress with its new VYD2311 clinical program.
NEW HAVEN, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights.
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.
